Gene · 1140
CHRNB1: cholinergic receptor nicotinic beta 1 subunit
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. CHRNB1: cholinergic receptor nicotinic beta 1 subunit. Genes, record 1140. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/1140
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P11230 | Acetylcholine receptor subunit beta | 501 | 13 | Ensembl, GeneID, HGNC |
Source UniProt
Patents43
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 41246 | P11230 | Espacenet |
| EP 4670794 A2 | 2025-12-31 | 26 | P11230 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 4263 | P11230 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 3823 | P11230 | Espacenet |
| US 12435124 B2 | 2025-10-07 | 33 | P11230 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 2879 | P11230 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 940 | P11230 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 5872 | P11230 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 5872 | P11230 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 940 | P11230 | Espacenet |
1 to 10 of 43
See all 43 patentsDrugs28
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ATRACURIUM | CHEMBL1360 | Muscle-type nicotinic acetylcholine receptor antagonist | ANTAGONIST | ChEMBL |
| ATRACURIUM BESYLATE | CHEMBL1200527 | Muscle-type nicotinic acetylcholine receptor antagonist | ANTAGONIST | ChEMBL |
| CISATRACURIUM | CHEMBL1201248 | Muscle-type nicotinic acetylcholine receptor antagonist | ANTAGONIST | ChEMBL |
| CISATRACURIUM BESYLATE | CHEMBL1200641 | Muscle-type nicotinic acetylcholine receptor antagonist | ANTAGONIST | ChEMBL |
| DECAMETHONIUM | CHEMBL1190 | Muscle-type nicotinic acetylcholine receptor partial agonist | PARTIAL AGONIST | ChEMBL |
| DECAMETHONIUM BROMIDE | CHEMBL1134 | Muscle-type nicotinic acetylcholine receptor partial agonist | PARTIAL AGONIST | ChEMBL |
| DOXACURIUM | CHEMBL1237123 | Muscle-type nicotinic acetylcholine receptor antagonist | ANTAGONIST | ChEMBL |
| DOXACURIUM CHLORIDE | CHEMBL1237099 | Muscle-type nicotinic acetylcholine receptor antagonist | ANTAGONIST | ChEMBL |
| GALLAMINE | CHEMBL360055 | Muscle-type nicotinic acetylcholine receptor antagonist | ANTAGONIST | ChEMBL |
| GALLAMINE TRIETHIODIDE | CHEMBL1200993 | Muscle-type nicotinic acetylcholine receptor antagonist | ANTAGONIST | ChEMBL |
1 to 10 of 28
See all 28 drugsTrials47
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07271472 | ROCURONIUM | ClinicalTrials.gov | ||
| NCT07143799 | CISATRACURIUM | ClinicalTrials.gov | ||
| NCT07121699 | ROCURONIUM | ClinicalTrials.gov | ||
| NCT07035301 | ROCURONIUM | ClinicalTrials.gov | ||
| NCT07033442 | ROCURONIUM | ClinicalTrials.gov | ||
| NCT06714981 | ROCURONIUM BROMIDE | ClinicalTrials.gov | ||
| NCT06514209 | CISATRACURIUM | ClinicalTrials.gov | ||
| NCT06214169 | CISATRACURIUM | ClinicalTrials.gov | ||
| NCT06212492 | CISATRACURIUM | ClinicalTrials.gov | ||
| NCT06203405 | CISATRACURIUM | ClinicalTrials.gov |
1 to 10 of 47
See all 47 trialsNIH grants314
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | CHRNB1 papers | Newest fiscal year |
|---|---|---|---|
| F30DA059437 | Subcortical targets involved in the action of psilocybin in learned and innate escape behaviors | 2 | 2025 |
| P30CA068485 | Cancer Center Support Grant | 2 | 2025 |
| P30EY008126 | Core Grant in Vision Research | 2 | 2025 |
| T32GM007454 | Medical Genetics Postdoctoral Fellowship | 2 | 2025 |
| U54NS115054 | Rare Disease Network for Myasthenia Gravis | 2 | 2025 |
| UL1TR001863 | Yale Clinical and Translational Science Award | 2 | 2025 |
| K01AA030083 | Mass Multivariate Derivation and Validation of AUD Biotypes using Developmental Imaging and Genomic Approaches | 1 | 2025 |
| KL2TR001862 | Institutional Career Development Core | 1 | 2025 |
| P01AG036695 | Molecular Regulation of Stem Cell Aging | 1 | 2025 |
| P01CA120964 | Molecular Pathogenesis of the Hamartoma Syndromes | 1 | 2025 |
1 to 10 of 314Source NIH's project files
See all 314 nih grantsPapers367
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Differential DNA Methylation and Delirium After Anesthesia and Surgery. | medRxiv | 2026 | 42369472 | PubTator, text mining | PubMed |
| Postsynaptic Congenital Myasthenic Syndrome Mimicking Limb-Girdle Muscular Dystrophy Associated with an Alternatively Spliced Exon in CHRNB1: A Case Report and Literature Review. | Children (Basel) | 2026 | 42354011 | PubTator, text mining | PubMed |
| Non-pterygium Escobar syndrome from compound-heterozygous CHRNG variants: genotype-phenotype insights. | Hum Genome Var | 2026 | 41826296 | PubTator, text mining | PubMed |
| Genetic Architecture of Myopia and Its Implications for Risk Stratification and Prognosis. | Diagnostics (Basel) | 2026 | 41750685 | PubTator, text mining | PubMed |
| Exploring molecular signatures in PURA syndrome using muscle proteomics and serum biomarkers. | J Neurol | 2026 | 41575592 | PubTator, text mining | PubMed |
| Comprehensive Genome-Wide Analysis of Shared Genetic Factors in Gastrointestinal and Neurodegenerative Diseases. | Brain Behav | 2025 | 41277170 | PubTator, text mining | PubMed |
| Precision Target Discovery for Migraine: An Integrated GWAS-eQTL-PheWAS Pipeline. | Molecules | 2025 | 41097341 | PubTator, text mining | PubMed |
| Biallelic CRELD1 variants cause severe muscle weakness and infantile epilepsy. | Brain Commun | 2025 | 40980404 | PubTator, text mining | PubMed |
| Clinical and genetic features of congenital myasthenic syndrome due to the muscle acetylcholine receptor genes. | Brain Dev | 2025 | 40768883 | PubTator, text mining | PubMed |
| Causal Variants in CHRNA1 and CHRNB1 Genes for Anti-acetylcholine Receptor Antibody Positive Myasthenia Gravis: Evidence from Bayesian Fine-Mapping and Genetic Association Study. | Mol Neurobiol | 2025 | 40279038 | PubTator, text mining | PubMed |
1 to 10 of 367
See all 367 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/1140
GET https://conductscience.org/api/genes/v1/1140/patents?page=2